Pierre Theurey
Lyon, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.
Journal: Endocrinology, diabetes & metabolism
Published: July 11, 2022
Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy.
Journal: The Journal of pharmacology and experimental therapeutics
Published: March 14, 2022
Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophy.
Journal: Journal of inherited metabolic disease
Published: February 14, 2022
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
Journal: Physiological reports
Published: November 29, 2021
Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.
Journal: Cell reports. Medicine
Published: May 31, 2021
Neuronal cell-based high-throughput screen for enhancers of mitochondrial function reveals luteolin as a modulator of mitochondria-endoplasmic reticulum coupling.
Journal: BMC biology
Published: April 17, 2020
Systems biology identifies preserved integrity but impaired metabolism of mitochondria due to a glycolytic defect in Alzheimer's disease neurons.
Journal: Aging cell
Published: February 21, 2018
Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases.
Journal: Cell death and differentiation
Published: August 11, 2017
Last Updated: 09/26/2026